Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity
Primary Purpose
Obesity
Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Euiiyin-tang
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity, Herbal product, Korean Medicine
Eligibility Criteria
Inclusion Criteria:
- Women aged 18-65 years old
- Patients applying to one of the followings 2.1. BMI 30kg/m2 or over 2.2. BMI 27-29.9kg/m2 with hypertension in a proper treatment and blood pressure controlled (SBP ≤ 145mmHg, DBP ≤ 95mmHg) 2.3. BMI 27-29.9kg/m2 with non-insulin-dependent diabetes mellitus and fasting blood glucose < 7.8mmol/L(140mg/dL) 2.4. BMI 27-29.9kg/m2 with hyperlipidemia in a proper treatment 2.5. BMI 27-39.9kg/m2 and Total cholesterol 236mg/dL or over or Triglyceride 150mg/dL or over at screening
- Agreed to low-calorie diet during the trial
- Written informed consent of the trial
Exclusion Criteria:
- Endocrine disease such as hypothyroidism, Cushing's syndrome, etc.
- Heart disease (heart failure, angina pectoris, myocardial infarction)
- Uncontrolled hypertension (SBP > 145 mmHg or DBP > 95 mmHg)
- Malignant tumour or lung disease
- Cholelithiasis
- Severe renal disability (SCr > 2.0 mg/dL)
- Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)
- Non-insulin-dependent diabetes mellitus and fasting blood sugar 7.8mmol/L (140 mg/dL) or over
- Narrow angle glaucoma
- History or existence of neurological or psychological disease (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.)
- History of stroke or temporary ischemic cardioplegia
- History or existence of eating disorder such as anorexia nervosa or bulimia nervosa, etc.
- Use of medication that could have effect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medication having effect on absorption, metabolism, excretion)
- Use of β--blocker or diuretic as hypertension medication within last 3 months
- Use of medication for central nervous system or central active weight reduction medication
- Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
- Difficult to measure anthropometric dimensions because of anatomical change such as resection
- Surgical history for weight reduction; bariatric surgery, etc.
- Unable to follow instructions of the trial as judged by investigator
- Women who were pregnant, lactating, planning a pregnancy or women of childbearing age who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.) (Women of childbearing age indicate within 2 years of menopause who did not receive hysterectomy, bilateral tubal ligation, bilateral oophorectomy, etc.)
- Use of other investigational product within last 1 month
- Reduction over 10% of the previous weight within 6 months
- Decided to stop smoking within last 3 months; however, keeping irregular smoking habit
Sites / Locations
- Gachon University Gil Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Euiiyin-tang
Placebo
Arm Description
powder type, 3 times per day before the meal, 12 weeks total
powder type, 3 times per day before the meal, 12 weeks total
Outcomes
Primary Outcome Measures
Weight reduction
Secondary Outcome Measures
C-reactive protein (CRP)
Blood pressure
Blood glucose
Waist/hip ratio
Waist circumference
Korean Obesity-related Quality of Life scale
Korean version of Eating Attitudes Test-26
Total cholesterol
Triglyceride
Visceral fat area
Using abdominal computed tomography
Subcutaneous fat area
Using abdominal computed tomography
Full Information
NCT ID
NCT01724099
First Posted
November 2, 2012
Last Updated
June 13, 2018
Sponsor
Kyunghee University Medical Center
Collaborators
Korea Health Industry Development Institute, Gachon University Gil Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01724099
Brief Title
Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity
Official Title
A Double Blind, Randomized, Multicenter, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Euiiyin-tang on Obese Patients
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
April 2013 (Actual)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
June 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kyunghee University Medical Center
Collaborators
Korea Health Industry Development Institute, Gachon University Gil Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The hypothesis of this study is obese patient with Euiiyin-tang for 12 weeks will show a superior reduction compared to those taking the placebo.
Detailed Description
This study has two arms, Euiiyin-tang and placebo group. Inclusion of 80 patient each arm. They will be screened at first visit. At the baseline, that is the second visit, they will be evaluated each outcomes including weight, waist circumference, lipid profile (total cholesterol, triglyceride), CRP (C-reactive protein), visceral fat area and subcutaneous fat area using abdominal computed tomography (CT), questionnaires of QoL (Quality of Life) and eating attitudes, etc. The Euiiyin-tang will provide to the patients from the baseline, it contains 4 weeks of serving. After 4 weeks, the visit 3, the evaluation procedure will be repeated except lipid profile, CRP, abdominal CT. Another Euiiyin-tang of 4 weeks will be given to the patient. The visit 4, 4 weeks after the visit 3, the same procedure will be repeated. The visit 5, 12 weeks after from the baseline, the patient will be evaluated including weight, waist circumference, lipid profile, CRP, visceral fat area and subcutaneous fat area using abdominal computed tomography, questionnaires of QoL and eating attitudes, etc.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, Herbal product, Korean Medicine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
149 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Euiiyin-tang
Arm Type
Experimental
Arm Description
powder type, 3 times per day before the meal, 12 weeks total
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
powder type, 3 times per day before the meal, 12 weeks total
Intervention Type
Drug
Intervention Name(s)
Euiiyin-tang
Intervention Description
Korean medicinal herbal drug
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo drug, same odor and formula as Euiiyin-tang
Primary Outcome Measure Information:
Title
Weight reduction
Time Frame
between baseline and 12 weeks
Secondary Outcome Measure Information:
Title
C-reactive protein (CRP)
Time Frame
baseline and 12 weeks
Title
Blood pressure
Time Frame
baseline, 4 weeks, 8 weeks, and 12 weeks
Title
Blood glucose
Time Frame
baseline and 12 weeks
Title
Waist/hip ratio
Time Frame
4 weeks, 8 weeks, and 12 weeks
Title
Waist circumference
Time Frame
baseline, 4 weeks, 8 weeks, and 12 weeks
Title
Korean Obesity-related Quality of Life scale
Time Frame
baseline and 12 weeks
Title
Korean version of Eating Attitudes Test-26
Time Frame
baseline and 12 weeks
Title
Total cholesterol
Time Frame
baseline and 12 weeks
Title
Triglyceride
Time Frame
baseline and 12 weeks
Title
Visceral fat area
Description
Using abdominal computed tomography
Time Frame
baseline and 12 weeks
Title
Subcutaneous fat area
Description
Using abdominal computed tomography
Time Frame
baseline and 12 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women aged 18-65 years old
Patients applying to one of the followings 2.1. BMI 30kg/m2 or over 2.2. BMI 27-29.9kg/m2 with hypertension in a proper treatment and blood pressure controlled (SBP ≤ 145mmHg, DBP ≤ 95mmHg) 2.3. BMI 27-29.9kg/m2 with non-insulin-dependent diabetes mellitus and fasting blood glucose < 7.8mmol/L(140mg/dL) 2.4. BMI 27-29.9kg/m2 with hyperlipidemia in a proper treatment 2.5. BMI 27-39.9kg/m2 and Total cholesterol 236mg/dL or over or Triglyceride 150mg/dL or over at screening
Agreed to low-calorie diet during the trial
Written informed consent of the trial
Exclusion Criteria:
Endocrine disease such as hypothyroidism, Cushing's syndrome, etc.
Heart disease (heart failure, angina pectoris, myocardial infarction)
Uncontrolled hypertension (SBP > 145 mmHg or DBP > 95 mmHg)
Malignant tumour or lung disease
Cholelithiasis
Severe renal disability (SCr > 2.0 mg/dL)
Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)
Non-insulin-dependent diabetes mellitus and fasting blood sugar 7.8mmol/L (140 mg/dL) or over
Narrow angle glaucoma
History or existence of neurological or psychological disease (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.)
History of stroke or temporary ischemic cardioplegia
History or existence of eating disorder such as anorexia nervosa or bulimia nervosa, etc.
Use of medication that could have effect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medication having effect on absorption, metabolism, excretion)
Use of β--blocker or diuretic as hypertension medication within last 3 months
Use of medication for central nervous system or central active weight reduction medication
Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
Difficult to measure anthropometric dimensions because of anatomical change such as resection
Surgical history for weight reduction; bariatric surgery, etc.
Unable to follow instructions of the trial as judged by investigator
Women who were pregnant, lactating, planning a pregnancy or women of childbearing age who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.) (Women of childbearing age indicate within 2 years of menopause who did not receive hysterectomy, bilateral tubal ligation, bilateral oophorectomy, etc.)
Use of other investigational product within last 1 month
Reduction over 10% of the previous weight within 6 months
Decided to stop smoking within last 3 months; however, keeping irregular smoking habit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yoon-kyung SONG, KMD
Organizational Affiliation
Gachon University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gachon University Gil Medical Center
City
Incheon
ZIP/Postal Code
405-760
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
32507436
Citation
Cheon C, Song YK, Ko SG. Efficacy and safety of Euiiyin-tang in Korean women with obesity: A randomized, double-blind, placebo-controlled, multicenter trial. Complement Ther Med. 2020 Jun;51:102423. doi: 10.1016/j.ctim.2020.102423. Epub 2020 May 21.
Results Reference
derived
PubMed Identifier
28637494
Citation
Cheon C, Jang S, Park JS, Ko Y, Kim DS, Lee BH, Song HJ, Song YK, Jang BH, Shin YC, Ko SG. Euiiyin-tang in the treatment of obesity: study protocol for a randomised controlled trial. Trials. 2017 Jun 21;18(1):289. doi: 10.1186/s13063-017-2039-8.
Results Reference
derived
Learn more about this trial
Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity
We'll reach out to this number within 24 hrs